[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
    "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754930844,
      "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
      "id": 136311902,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372801568/image_1372801568.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=805280b5a0b76fd255f456dfe0b553ed225e62cd1ac2e478318feb729a8a65fb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754929800,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "id": 136337083,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=805280b5a0b76fd255f456dfe0b553ed225e62cd1ac2e478318feb729a8a65fb"
    }
  },
  {
    "ts": null,
    "headline": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
    "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
    "url": "https://finnhub.io/api/news?id=e818c7ab040c6d6faecea6bdeee9326ce5f2a80ffa7e326f236e15f379470703",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917800,
      "headline": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
      "id": 136295231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
      "url": "https://finnhub.io/api/news?id=e818c7ab040c6d6faecea6bdeee9326ce5f2a80ffa7e326f236e15f379470703"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity",
    "summary": "Regeneron's Q2 earnings shine with DUPIXENT's growth offsetting EYLEA's decline.",
    "url": "https://finnhub.io/api/news?id=dfd0d734d11465aa8372cdb278884ec59ce12c7218257f843ebfaf74f32de0bb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754912219,
      "headline": "Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity",
      "id": 136295603,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/90948562/image_90948562.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron's Q2 earnings shine with DUPIXENT's growth offsetting EYLEA's decline.",
      "url": "https://finnhub.io/api/news?id=dfd0d734d11465aa8372cdb278884ec59ce12c7218257f843ebfaf74f32de0bb"
    }
  },
  {
    "ts": null,
    "headline": "Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments",
    "summary": "Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a review of recent accomplishments and anticipated upcoming developments.",
    "url": "https://finnhub.io/api/news?id=8aea7d9c110d168f5f3f9d4fbc4edd8c02e0ca02212bb2b776802c5de81eec12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754910000,
      "headline": "Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments",
      "id": 136294464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a review of recent accomplishments and anticipated upcoming developments.",
      "url": "https://finnhub.io/api/news?id=8aea7d9c110d168f5f3f9d4fbc4edd8c02e0ca02212bb2b776802c5de81eec12"
    }
  }
]